

Resource Summary Report

Generated by [dkNET](#) on Jul 29, 2026

NOD.Cg-Prkdc^{scid} Il2rg/ JicTac

RRID:IMSR_TAC:HSCFTL-NOG

Type: Organism

Proper Citation

RRID:IMSR_TAC:HSCFTL-NOG

Organism Information

URL: <https://www.taconic.com/mouse-model/hunog>

Proper Citation: RRID:IMSR_TAC:HSCFTL-NOG

Description: Mus musculus with name NOD.Cg-Prkdc^{scid} Il2rg/ JicTac from IMSR.

Species: Mus musculus

Notes: gene symbol note: ; mutant strain:

Catalog Number: TAC:HSCFTL-NOG

Database: Taconic Biosciences

Database Abbreviation: TAC

Availability: live

Organism Name: NOD.Cg-Prkdc^{scid} Il2rg/ JicTac

Record Creation Time: 20250513T053521+0000

Record Last Update: 20260725T044221+0000

Ratings and Alerts

No rating or validation information has been found for NOD.Cg-Prkdc^{scid} Il2rg/ JicTac.

No alerts have been found for NOD.Cg-Prkdc^{scid} Il2rg/ JicTac.

Data and Source Information

Source: [Integrated Animals](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Bröker J, et al. (2025) Discovery of BI-2493, a Pan-KRAS Inhibitor Showing In Vivo Efficacy. *Journal of medicinal chemistry*, 68(15), 15649.

Jakobsen MK, et al. (2025) Stochastic demethylation and redundant epigenetic suppressive mechanisms generate highly heterogeneous responses to pharmacological DNA methyltransferase inhibition. *Journal of experimental & clinical cancer research : CR*, 44(1), 21.

Hollander JF, et al. (2025) Serially Quantifying TERT Rearrangement Breakpoints in ctDNA Enables Minimal Residual Disease Monitoring in Patients with Neuroblastoma. *Cancer research communications*, 5(1), 167.

King LA, et al. (2024) V α 2 T-cell engagers bivalent for V α 2-TCR binding provide anti-tumor immunity and support robust V α 9V α 2 T-cell expansion. *Frontiers in oncology*, 14, 1474007.

Noel S, et al. (2024) Kidney Immune Cell Characterization of Humanized Mouse Models. *Kidney360*, 5(1), 96.

Metz C, et al. (2024) Pharmacokinetic and Environmental Risk Assessment of Prime-2-CoV, a Non-Replicating Orf Virus-Based Vaccine against SARS-CoV-2. *Vaccines*, 12(5).

Jancewicz I, et al. (2024) New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo. *Cancer immunology, immunotherapy : CII*, 73(2), 30.

Pusch FF, et al. (2024) Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models. *Molecular cancer therapeutics*, 23(4), 507.

Danielli SG, et al. (2024) Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer. *Molecular cancer therapeutics*, 23(6), 864.

Skidmore LK, et al. (2024) Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody-Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer. *Molecular cancer therapeutics*, 23(12), 1842.

Gray E, et al. (2023) SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models. *Journal for immunotherapy of cancer*, 11(10).

Vasciaveo A, et al. (2023) OncoLoop: A Network-Based Precision Cancer Medicine Framework. *Cancer discovery*, 13(2), 386.

Zhang W, et al. (2022) A Novel B7-H6-Targeted IgG-Like T Cell-Engaging Antibody for the Treatment of Gastrointestinal Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 28(23), 5190.